CENTENE CORPCNC

A massive $6.7 billion^a goodwill impairment charge decimated Centene Corporation's bottom line in FY2025, driving a steep net loss of -$13.53 per share despite record revenues. This stark divergence highlights a central investment reality: while the managed care giant consistently drives top-line expansion across government-sponsored programs, escalating medical costs and Medicaid acuity are severely testing its core profitability.

Total revenue surged from $126.0 billion in FY2021 to $194.8 billion^b in FY2025, fueled by strategic acquisitions like the $2.6 billion purchase of Magellan Health and aggressive expansion in the Health Insurance Marketplace. Yet, the cost of delivering care outpaced this growth. Centene's Health Benefits Ratio (HBR) climbed from 87.7% in FY2022 to a bruising 91.9% in FY2025. To combat margin pressures, management executed cost-cutting initiatives that reduced the Selling, General, and Administrative (SG&A) expense ratio to 7.0% by Q3 2025. Simultaneously, the core managed care base faced industry headwinds, with membership contracting by 3% to 27.6 million in FY2025 following widespread Medicaid eligibility redeterminations.

Despite generating $5.1 billion^c in operating cash flow during FY2025, the heavy impairment charges and elevated medical utilization weighed heavily on equity values. At the close of FY2025, the market priced Centene at $41.15 per share, assigning the healthcare provider a $20.2 billion market capitalization amid its severe earnings deficit.